Citadel Advisors
HSCS icon

Citadel Advisors’s Heart Test Laboratories HSCS Stock Holding History

Citadel Advisors’s Portfolio HSCS Stock Details HSCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,684
Closed -$70.1K – 13347
2025
Q2 		$70.1K Buy
+18,684
New +$65.3K ﹤0.01% 11588
2024
Q2 		– Sell
-1,231
Closed -$14.4K – 14756
2024
Q1 		$14.4K Buy
1,231
+922
+298% +$12.1K ﹤0.01% 13247
2023
Q4 		$5.28K Buy
309
+3
+1% +$74 ﹤0.01% 13440
2023
Q3 		$13.2K Buy
+306
New +$23.7K ﹤0.01% 12930
2022
Q3 		– Sell
-234
Closed -$44K – 13035
2022
Q2 		$44K Buy
+234
New +$45.2K ﹤0.01% 12012

Other funds holding HSCS

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
TA
TFB Advisors Overland Park, Kansas $191M AUM 18.47% 1-Year Est. Return
ASW
Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
RFG
REAP Financial Group Austin, Texas $507M AUM 18.73% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's HSCS Position: Q3 2025 in Review

Citadel Advisors sold out of Heart Test Laboratories (HSCS) in Q3 2025, closing a stake of 18,684 shares — an estimated $70.1K sold.

Citadel Advisors first reported a position in HSCS in Q2 2022 and held it in 5 quarters. The position peaked at $70.1K in Q2 2025. 12 funds tracked by Wall St. Rank hold HSCS as of Q3 2025.

  • Citadel Advisors reported no remaining Heart Test Laboratories position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 18,684 Heart Test Laboratories shares in Q3 2025, an estimated $70.1K.
  • Citadel Advisors first reported a position in Heart Test Laboratories in Q2 2022 and held it in 5 quarters.
  • Citadel Advisors's Heart Test Laboratories position peaked at $70.1K in Q2 2025.
  • 12 funds tracked by Wall St. Rank held Heart Test Laboratories as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.